drugset / Trial / NCT03672695
Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the safety profile, tolerability and the Recommended Phase 2 Dose of the combination S64315 with venetoclax in patients with Acute Myeloid Leukaemia.
Timeline
- Start
- 2018-11-28
- Primary completion
- 2022-11-12
- Completion
- 2023-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MIK665 | Unknown | 50 mg | Intravenous |
| Subject | MIK665 | Unknown | 250 mg | Intravenous |
| Subject | Venetoclax | Small molecule | 100 mg | Oral |
| Subject | Venetoclax | Small molecule | 600 mg | Oral |